
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/580225/publications.pdf Version: 2024-02-01



ARDAHAM RURINSTEIN

#	Article	IF	CITATIONS
1	Synchronizing the release rates of topotecan and paclitaxel from a self-eroding crosslinked chitosan – PLGA platform. International Journal of Pharmaceutics, 2022, 623, 121945.	5.2	2
2	Generalizing research findings for enhanced reproducibility: an approach based on verbal alternative representations. Scientometrics, 2021, 126, 4137-4151.	3.0	6
3	Controlling the release rate of topotecan from PLGA spheres and increasing its cytotoxicity towards glioblastoma cells by co-loading with calcium chloride. International Journal of Pharmaceutics, 2021, 602, 120616.	5.2	4
4	Synchronizing the release rates of salicylate and indomethacin from degradable chitosan hydrogel and its optimization by definitive screening design. European Journal of Pharmaceutical Sciences, 2018, 125, 102-109.	4.0	13
5	The effect of linker type and recognition peptide conjugation chemistry on tissue affinity and cytotoxicity of charged polyacrylamide. Journal of Controlled Release, 2017, 257, 102-117.	9.9	8
6	Increasing the affinity of cationized polyacrylamide-paclitaxel nanoparticles towards colon cancer cells by a surface recognition peptide. International Journal of Pharmaceutics, 2017, 531, 281-291.	5.2	25
7	A Generalization Approach to Reproducibility Claims. SSRN Electronic Journal, 2017, , .	0.4	1
8	A multifactorial analysis of complex pharmaceutical platforms: an application of design of experiments to targetable polyacrylamide and ultrasound contrast agents. Polymers for Advanced Technologies, 2015, 26, 898-905.	3.2	2
9	The Anti-Inflammatory Activity of a Novel Fused-Cyclopentenone Phosphonate and Its Potential in the Local Treatment of Experimental Colitis. Gastroenterology Research and Practice, 2015, 2015, 1-10.	1.5	2
10	Thermotropic behavior of celecoxib-loaded beta-casein micelles: relevance to the improved bioavailability. European Journal of Nanomedicine, 2015, 7, .	0.6	8
11	Multi-modal detection of colon malignancy by NIR-tagged recognition polymers and ultrasound contrast agents. International Journal of Pharmaceutics, 2015, 478, 504-516.	5.2	7
12	Nanoparticles in the Gastrointestinal Tract. Frontiers in Nanobiomedical Research, 2014, , 115-151.	0.1	1
13	Beta-casein nanocarriers of celecoxib for improved oral bioavailability. European Journal of Nanomedicine, 2014, 6, .	0.6	25
14	Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT–PNA molecular beacons. Cancer Letters, 2014, 352, 90-96.	7.2	97
15	Synthesis and characterization of near IR fluorescent albumin nanoparticles for optical detection of colon cancer. Materials Science and Engineering C, 2013, 33, 923-931.	7.3	27
16	Molybdenum-Mediated Deconjugation of α,β-Unsaturated Fused-Cyclopentenone Phosphonates. Synthesis, 2012, 44, 1258-1262.	2.3	1
17	The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide. European Journal of Pharmaceutical Sciences, 2012, 47, 904-913.	4.0	19
18	Boron Containing Compounds as Protease Inhibitors. Chemical Reviews, 2012, 112, 4156-4220.	47.7	352

#	Article	IF	CITATIONS
19	Detection of Endogenous <i>K-ras</i> mRNA in Living Cells at a Single Base Resolution by a PNA Molecular Beacon. Molecular Pharmaceutics, 2012, 9, 685-693.	4.6	80
20	Detecting a Secreted Gastric Cancer Biomarker Molecule by Targeted Nanoparticles for Real-Time Diagnostics. Pharmaceutical Research, 2012, 29, 983-993.	3.5	9
21	Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. Journal of Drug Targeting, 2011, 19, 859-873.	4.4	11
22	Enhanced Transferrin Receptor Expression by Proinflammatory Cytokines in Enterocytes as a Means for Local Delivery of Drugs to Inflamed Gut Mucosa. PLoS ONE, 2011, 6, e24202.	2.5	59
23	A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs. Journal of Pharmacy and Pharmacology, 2011, 35, 607-609.	2.4	15
24	Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6518-6523.	2.2	7
25	Specific Detection of Gastric α-Antitrypsin by Immobilized Trypsin on PolyHEMA Films. Molecular Pharmaceutics, 2010, 7, 944-952.	4.6	1
26	Direct formation of cyclobutenylphosphonates from 1-alkynylphosphonates and Cp2ZrCl2/2EtMgCl/2CuCl. Tetrahedron Letters, 2009, 50, 867-869.	1.4	18
27	Transferrin as a Luminal Target for Negatively Charged Liposomes in the Inflamed Colonic Mucosa. Molecular Pharmaceutics, 2009, 6, 1083-1091.	4.6	121
28	Mo(CO)6-Mediated Intramolecular Pausonâ^'Khand Reaction of Substituted Diethyl 3-Allyloxy-1-Propynylphosphonates. Journal of Organic Chemistry, 2009, 74, 1029-1033.	3.2	18
29	The Metastatic Stage-dependent Mucosal Expression of Sialic Acid is a Potential Marker for Targeting Colon Cancer with Cationic Polymers. Pharmaceutical Research, 2008, 25, 379-386.	3.5	18
30	Synthesis of 3-hydroxy-1-alkenylboronates via phosphine stabilized borylzirconacyclopropenes. Chemical Communications, 2008, , 5589.	4.1	12
31	Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. Journal of Biomedical Materials Research - Part A, 2007, 83A, 414-422.	4.0	94
32	Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 1311-norcholesterol. Journal of Controlled Release, 2007, 123, 116-122.	9.9	39
33	Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. Journal of Drug Targeting, 2006, 14, 155-163.	4.4	69
34	Chitosanâ^'Pentaglycineâ^'Phenylboronic Acid Conjugate:Â A Potential Colon-Specific Platform for Calcitonin. Bioconjugate Chemistry, 2006, 17, 1000-1007.	3.6	37
35	Pharmacologically active boranes. Pure and Applied Chemistry, 2006, 78, 1425-1453.	1.9	20
36	Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti-Cancer Drugs, 2006, 17, 609-619.	1.4	6

#	Article	IF	CITATIONS
37	Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. European Journal of Pharmaceutical Sciences, 2006, 28, 204-211.	4.0	44
38	Crosslinked chitosan implants as potential degradable devices for brachytherapy: In vitro and in vivo analysis. Journal of Controlled Release, 2006, 111, 281-289.	9.9	81
39	α-Amino boronates as cyanoborane complexes: crystal structure and inhibition properties for the serine proteases: α-chymotrypsin and trypsin. Applied Organometallic Chemistry, 2006, 20, 459-462.	3.5	6
40	Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers. Journal of Controlled Release, 2005, 106, 14-25.	9.9	26
41	Local Prevention of Oxidative Stress in the Intestinal Epithelium of the Rat by Adhesive Liposomes of Superoxide Dismutase and Tempamine. Molecular Pharmaceutics, 2005, 2, 2-11.	4.6	31
42	Colonic drug delivery. Drug Discovery Today: Technologies, 2005, 2, 33-37.	4.0	47
43	Noncovalent inhibition of the serine proteases, α-chymotrypsin and trypsin by trifluoro(organo)borates. Organic and Biomolecular Chemistry, 2005, 3, 941-944.	2.8	18
44	Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes. Pharmaceutical Research, 2004, 21, 447-453.	3.5	122
45	Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer–doxorubicin conjugates to human colon cancer cells. European Journal of Cancer, 2004, 40, 148-157.	2.8	95
46	Combined1H,13C and11B NMR and mass spectral assignments of boronate complexes ofD-(+)-glucose,D-(+)-mannose, methyl-?-D-glucopyranoside, methyl-?-D-galactopyranoside and methyl-?-D-mannopyranoside. Magnetic Resonance in Chemistry, 2003, 41, 1015-1020.	1.9	11
47	A study of the effect on nucleophilic hydrolytic activity of pancreatic elastase, trypsin, chymotrypsin, and leucine aminopeptidase by boronic acids in the presence of arabinogalactan: a subsequent study on the hydrolytic activity of chymotrypsin by boronic acids in the presence of mono-, di-, and trisaccharides. Bioorganic Chemistry. 2003. 31. 464-474.	4.1	17
48	Regional peptide uptake study in the rat intestinal mucosa: glatiramer acetate as a model drug. Pharmaceutical Research, 2002, 19, 832-837.	3.5	6
49	The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells. Pharmaceutical Research, 2002, 19, 1114-1122.	3.5	44
50	The Colon as a Possible Target for Orally Administered Peptide and Protein Drugs. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 499-552.	2.2	62
51	Enhanced Biorecognition and Internalization of HPMA Copolymers Containing Multiple or Multivalent Carbohydrate Side-Chains by Human Hepatocarcinoma Cells. Bioconjugate Chemistry, 2001, 12, 890-899.	3.6	73
52	Adsorption of Cationized Bovine Serum Albumin onto Epithelial Crypt Fractions of the Rat Colon. Journal of Pharmaceutical Sciences, 2001, 90, 1516-1522.	3.3	4
53	Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. Journal of Controlled Release, 2001, 70, 139-147.	9.9	30
54	The Effect of Adhesive Antioxidant Enzymes on Experimental Colitis in the Rat. ACS Symposium Series, 2000, , 78-89.	0.5	0

#	Article	IF	CITATIONS
55	Natural polysaccharides as targeting tools of drugs to the human colon. Drug Development Research, 2000, 50, 435-439.	2.9	51
56	Phosphated crosslinked guar for colon-specific drug delivery. Journal of Controlled Release, 2000, 63, 121-127.	9.9	115
57	Phosphated crosslinked guar for colon-specific drug delivery. Journal of Controlled Release, 2000, 63, 129-134.	9.9	104
58	Relation between colonic inflammation severity and total low-molecular-weight antioxidant profiles in experimental colitis. Digestive Diseases and Sciences, 2000, 45, 1180-1187.	2.3	26
59	The effect of local attachment of cationized antioxidant enzymes on experimental colitis in the rat. Pharmaceutical Research, 2000, 17, 1077-1084.	3.5	15
60	Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine. Pharmaceutical Research, 2000, 17, 1071-1076.	3.5	20
61	Drug Targeting by Surface Cationization. Critical Reviews in Therapeutic Drug Carrier Systems, 2000, 17, 41.	2.2	77
62	Characterization of crosslinked guar by thermal analysis. Carbohydrate Research, 1999, 316, 6-13.	2.3	41
63	Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Molecular and Cellular Biochemistry, 1999, 194, 185-191.	3.1	68
64	Low swelling, crosslinked guar and its potential use as colon-specific drug carrier. Pharmaceutical Research, 1998, 15, 1019-1025.	3.5	80
65	Migration of Adhesive and Nonadhesive Particles in the Rat Intestine under Altered Mucus Secretion Conditions. Journal of Pharmaceutical Sciences, 1998, 87, 453-456.	3.3	29
66	The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. International Journal of Pharmaceutics, 1998, 176, 21-30.	5.2	25
67	forms1The results reported here form part of the dissertation projects of M.B. and T.Ń., completed in partial fulfilment of the requirements of their respective PhD and MSc degrees at the Hebrew University of Jerusalem. The study has been presented in part at the 22nd International Symposium on Controlled Release of Bioactive Materials. Seattle, WA, 1995.1, Journal of Controlled Release, 1997, 45.	9.9	22
68	57-64. The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. Journal of Controlled Release, 1997, 46, 59-73.	9.9	82
69	The use of scintigraphy to provide "proof of concept" for novel polysaccharide preparations designed for colonic drug delivery. Pharmaceutical Research, 1997, 14, 103-107.	3.5	59
70	The effect of intestinal bacteria adherence on drug diffusion through solid films under stationary conditions. Pharmaceutical Research, 1997, 14, 503-507.	3.5	5
71	Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. International Journal of Pharmaceutics, 1997, 154, 235-243.	5.2	34
72	Absorption enhancement of captopril in the rat colon as a putative method for captopril delivery by extended release formulations. International Journal of Pharmaceutics, 1996, 143, 101-106.	5.2	8

#	Article	IF	CITATIONS
73	Cross-linked chondroitin sulphate: characterization for drug delivery purposes. Biomaterials, 1995, 16, 473-478.	11.4	75
74	Approaches and Opportunities in Colon-Specific Drug Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 1995, 12, 101-149.	2.2	144
75	Mucus gel thickness and turnover in the gastrointestinal tract of the rat: response to cholinergic stimulus and implication for mucoadhesion. Pharmaceutical Research, 1994, 11, 794-799.	3.5	71
76	Protection of the Rat Jejunal Mucosa against Oxidative Injury by Cationized Superoxide Dismutase. Journal of Pharmaceutical Sciences, 1993, 82, 1285-1287.	3.3	11
77	Enzymatic cleavage of disaccharide side groups in insoluble synthetic polymers: A new method for specific delivery of drugs to the colon. Biomaterials, 1993, 14, 483-490.	11.4	14
78	In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharmaceutical Research, 1993, 10, 258-263.	3.5	202
79	Prevention of oxidative damage in the rat jejunal mucosa by pectin. British Journal of Nutrition, 1993, 69, 789-800.	2.3	25
80	Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharmaceutical Research, 1992, 09, 276-278.	3.5	91
81	Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery. International Journal of Pharmaceutics, 1992, 84, 141-150.	5.2	108
82	In Vitro Release and Intestinal Absorption of Physostigmine Salicylate from Submicron Emulsions. Journal of Pharmaceutical Sciences, 1991, 80, 643-647.	3.3	21
83	Enhanced stability of physostigmine salicylate in submicron o/w emulsion. International Journal of Pharmaceutics, 1990, 65, 169-175.	5.2	10
84	Microbially controlled drug delivery to the colon. Biopharmaceutics and Drug Disposition, 1990, 11, 465-475.	1.9	149
85	Improved intestinal cannula for drug delivery studies in the dog. Journal of Pharmacological Methods, 1988, 19, 213-217.	0.7	6
86	Gastric Emptying of Nondigestible Solids in the Fasted Dog. Journal of Pharmaceutical Sciences, 1987, 76, 117-122.	3.3	57
87	A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study. Journal of Controlled Release, 1986, 4, 33-38.	9.9	7
88	Computerized Model for Evaluating the Kinetics of In Vitro Release of Valpromide from Controlled-Release Tablets Under Nonsink Conditions. Journal of Pharmaceutical Sciences, 1986, 75, 959-961.	3.3	3
89	Controlled Drug Delivery. Progress in Clinical Biochemistry and Medicine, 1986, , 71-107.	0.5	10
90	A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. International Journal of Pharmaceutics, 1985, 23, 25-33.	5.2	21

#	Article	IF	CITATIONS
91	Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharmaceutics and Drug Disposition, 1984, 5, 177-183.	1.9	18
92	Rapid Gas Chromatographic Assay for Monitoring Valproic Acid and Valpromide in Plasma. Journal of Pharmaceutical Sciences, 1984, 73, 991-993.	3.3	32
93	Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. European Journal of Clinical Pharmacology, 1984, 27, 501-503.	1.9	30
94	A new method for stability determination of semi-solid emulsions, using conductivity measurements. Colloids and Surfaces, 1981, 3, 221-231.	0.9	5